tiprankstipranks
Cellectis SA (DE:ZVAA)
FRANKFURT:ZVAA

Cellectis SA Stock Price & Analysis

0 Followers

ZVAA Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€2.25 - €13.08
Previous Close€2.26
Volume0.00
Average Volume (3M)150.00
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)€129.44M
Total Debt (Recent Filing)€85.36M
P/E Ratio-1.0
Beta1.87
Next EarningsNov 15, 2022
EPS Estimate-€0.33
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-2.19
Shares Outstanding45,510,810
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. Volume0
30 Day Avg. Volume150
P/B Ratio0.72
P/S Ratio7.63
P/CF Ratio266.40
P/FCF Ratio-1.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside757.45% Upside
Rating ConsensusModerate Buy
AlphaN/A
Number of Analyst Covering5


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

ZVAA FAQ

What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was €2.25 and its highest was €13.08 in the past 12 months.
    What is Cellectis SA’s market cap?
    Currently, no data Available
    When is Cellectis SA’s upcoming earnings report date?
    Cellectis SA’s upcoming earnings report date is Nov 15, 2022 which is in 43 days.
      How were Cellectis SA’s earnings last quarter?
      Cellectis SA released its earnings results on Aug 04, 2022. The company reported -€0.428 earnings per share for the quarter, beating the consensus estimate of -€0.524 by €0.096.
        Is Cellectis SA overvalued?
        According to Wall Street analysts Cellectis SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Cellectis SA pay dividends?
          Cellectis SA does not currently pay dividends.
          What is Cellectis SA’s EPS estimate?
          Cellectis SA’s EPS estimate is -€0.33.
            How many shares outstanding does Cellectis SA have?
            Cellectis SA has 45,475,310 shares outstanding.
              What happened to Cellectis SA’s price movement after its last earnings report?
              Cellectis SA reported an EPS of -€0.428 in its last earnings report, beating expectations of -€0.524. Following the earnings report the stock price went down -5.806%.
                Which hedge fund is a major shareholder of Cellectis SA?
                Among the largest hedge funds holding Cellectis SA’s share is Bpifrance SA. It holds Cellectis SA’s shares valued at 1M.

                  ---

                  Cellectis SA Stock Analysis

                  Smart ScoreNeutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  6

                  Analyst Consensus

                  Moderate Buy
                  Average Price Target: €19.38

                  Blogger Sentiment

                  N/A
                  Currently Not Enough Data Available

                  Insider Transactions

                  N/A
                  Currently Not Enough Data Available

                  News Sentiment

                  Neutral
                  Bullish 50% Bearish 50%

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -81.83%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -50.93%
                  Trailing 12-Months
                  Asset Growth
                  -29.87%
                  Trailing 12-Months
                  The Cellectis SA Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Cellectis SA

                  Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Pfizer
                  Affimed
                  Bluebird Bio
                  Intellia Therapeutics

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis